APA (7th ed.) Citation

VS, M., DA, B., L, I., G, K., E, L., D, P., . . . N, T. (2023). Design and population of the VALOR-CKD study: A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 38(6), 1448. https://doi.org/10.1093/ndt/gfac289

Chicago Style (17th ed.) Citation

VS, Mathur, et al. "Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 38, no. 6 (2023): 1448. https://doi.org/10.1093/ndt/gfac289.

MLA (9th ed.) Citation

VS, Mathur, et al. "Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 38, no. 6, 2023, p. 1448, https://doi.org/10.1093/ndt/gfac289.